Joshua A. Linton, PharmD

Director, US Medical Oncology, CRC/Pancreatic Cancer, GI Targeted Therapies
Bristol Myers Squibb

Poster(s):

• (334) Nivolumab plus Ipilimumab as a First-line Treatment for MSI-H/dMMR Metastatic Colorectal Cancer: a Cost-per-Outcome Analysis
  Wednesday, October 29, 2025